Arimidex News
New Results From One Of The World's Largest Breast Cancer Trials ... - CNW Telbec (Communiqués de presse)
Benefits of Arimidex(R) over tamoxifen in preventing all forms of breast cancer recurrence increase over time, and persist - women in the trial taking ...
Breast cancer drug 'more effective' - The Press Association
Breast cancer drug Arimidex is superior to the more common tamoxifen when it comes to long-term benefits, research has found. A study in The Lancet Oncology ...
Arimidex Outperforms Tamoxifen In Breast Cancer Study - Dog Flu Diet and Diseases
December 14, 2007 - Results of a new study find that the breast cancer drug Arimidex, works better than tamoxifen when it comes to treating women with ...
Data Show ARIMIDEX（R） （Anastrozole） Continues To Be Superior ... - 金融界
14 /PRNewswire-FirstCall/ -- Data released today show a continued benefit of ARIMIDEX when compared to tamoxifen in treating postmenopausal women with ...
AstraZeneca: Data shows Arimidex continues to be superior to Tamoxifen - CNNMoney.com
14, 2007 (Thomson Financial delivered by Newstex) -- AstraZeneca (NYSE:AZN) Plc late Friday said new data shows the continued benefit of Arimidex when ...
Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay - U.S. News & World Report
14 (HealthDay News) -- The aromatase inhibitor drug Arimidex continues to outpace the old standard tamoxifen when it comes to preventing recurrences of ...
Arimidex® Reduces Risk of Breast Cancer Recurrence - Cancer Consultants (press release)
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) Study was designed to compare the aromatase inhibitor Arimidex to tamoxifen in the initial hormonal ...
astrazeneca Gets Arimidex Extension - FDA news (subscription)
astrazeneca said the FDA has granted it another six months of patent protection for its breast cancer drug Arimidex. The patent extension through June 2010 ...
astrazeneca receives six months pediatric exclusivity patent ... - News-Medical.net
Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX (granted in ...
Market Report -- In Play (AZN) - MSN Money
AstraZeneca announces it receives six months pediatric exclusivity patent extension for ARIMIDEX from the FDA Co announces that the FDA has granted an ...
Arimidex RSS Feed